The Ebola virus (EBOV) and Marburg virus (MARV) have been in circulation in Africa for several decades and are the cause of numerous outbreaks. There has been very little research on the role of domestic animals in their transmission to humans, but studies have only been conducted in dogs and pigs where relatively high levels of IgG was detected. These levels suggest that ruminants, which have not been studied, should also be investigated. This study aims at evaluating the circulation of MARV and EBOV in dogs, sheep and goats and to assess their exposure to these two viruses. Between November 2018 and March 2023, a total of 448 domestic animal sera or plasma samples, including 128 dogs, 222 goats and 98 sheep, were analyzed by serological and molecular methods. The Luminex technique was employed for the detection of IgG antibodies against EBOV NP, GP, MARV GP and VP40, while EBOV specific and pan-filovirus polymerase chain reaction amplification was used for molecular analysis. All samples tested negative for EBOV and MARV RNA. However, our results showed that 2/128 (1.5%) dogs, 1/222 (0.4%) goats and 3/98 (3.1%) sheep displayed NP and GP anti-EBOV antibodies. In addition, 2/128 (1.5%) dogs displayed GP and VP40 anti-MARV antibodies, while no antibodies were detected in goats and sheep. Over all, these results suggest that dogs and small ruminants are naturally exposed to EBOV and MARV. In the absence of clinically sick individuals, the presence of IgG-positive animals suggests various sources of exposure, such as contaminated fruits with the urine and saliva of bats or dead bats fallen on the ground ate by dogs. These contaminated substrates are both consumed by both dogs and small ruminants. The findings provide new insights into the circulation and exposure of EBOV and MARV in domestic animals, emphasising their potential use as sentinels. Furthermore, they prompt significant considerations regarding the potential risk to humans in this region.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882094PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0314801PLOS

Publication Analysis

Top Keywords

ebov marv
16
small ruminants
12
dogs
9
domestic animals
8
goats sheep
8
2/128 15%
8
15% dogs
8
dogs small
8
ebov
7
marv
6

Similar Publications

The Ebola virus (EBOV) and Marburg virus (MARV) have been in circulation in Africa for several decades and are the cause of numerous outbreaks. There has been very little research on the role of domestic animals in their transmission to humans, but studies have only been conducted in dogs and pigs where relatively high levels of IgG was detected. These levels suggest that ruminants, which have not been studied, should also be investigated.

View Article and Find Full Text PDF

: Orthoebolaviruses and orthomarburgviruses are filoviruses that can cause viral hemorrhagic fever and significant morbidity and mortality in humans. The evaluation and deployment of vaccines to prevent and control Ebola and Marburg outbreaks must be informed by an understanding of the transmission and natural history of the causative infections, but little is known about the burden of asymptomatic infection or undiagnosed disease. This systematic review of the published literature examined the seroprevalence of antibodies to orthoebolaviruses and orthomarburgviruses in sub-Saharan Africa.

View Article and Find Full Text PDF

Ebola and Marburg (EBOV and MARV) filoviral infections lead to fatal hemorrhagic fevers and have caused over 30 outbreaks in the last 50 years. Currently, there are no FDA-approved small molecule therapeutics for effectively treating filoviral diseases. To address this unmet medical need, we have conducted a systematic structural optimization of an early lead compound, -(4-(4-methylpiperidin-1-yl)-3-(trifluoromethyl)phenyl)-4-(morpholinomethyl)benzamide (), borne from our previously reported hit-to-lead effort.

View Article and Find Full Text PDF
Article Synopsis
  • Filoviruses, like Ebola virus (EBOV), cause filovirus disease (FVD) and pose significant global health threats, but studying them has been challenging due to safety restrictions.
  • A new research tool involving a modified vesicular stomatitis virus (VSV-filo GP) allows researchers to safely explore the interactions and immune responses related to filovirus infections outside high-security labs.
  • The study utilizes interferon α/β receptor-deficient (Ifnar) mice to examine different methods of infection and disease progression, providing a cost-effective and manageable way to advance filovirus research.
View Article and Find Full Text PDF

Generation, Recovery, and Propagation of a Recombinant Vesicular Stomatitis Virus Expressing the Marburg Virus Glycoprotein.

Methods Mol Biol

November 2024

Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.

Vesicular stomatitis virus (VSV)-based vaccination has shown protective efficacy against filovirus infection. Following the approval of a VSV-based vaccine against Ebola virus, there have been efforts toward applying the same platform for other filoviruses, including Marburg virus (MARV) and Sudan virus. Because these vaccines express filovirus glycoproteins, they are also a valuable tool to study filovirus entry under biosafety level 2 conditions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!